NCT06054035: SGLT2 Inhibition in Addition to Lifestyle Intervention and Risk for Complications in Subtypes of Patients With Prediabetes |
|
|
| Recruiting | 4 | 182 | Europe | Dapagliflozin (Forxiga®), Placebo matching Dapaglifolzin, Lifestyle Intervention | University Hospital Tuebingen, German Federal Ministry of Education and Research, German Center for Diabetes Research, AstraZeneca | Type2diabetes, PreDiabetes, Renal Failure | 03/26 | 12/26 | | |
NCT04467515: A Study to Evaluate Safety, Tolerability, Dosimetry, and Preliminary Efficacy of the HER2 Directed Radioligand CAM-H2 in Patients With Advanced/Metastatic HER2-Positive Breast, Gastric, and Gastro-Esophageal Junction (GEJ) Cancer |
|
|
| Terminated | 1/2 | 13 | Canada, US | CAM-H2 | Precirix | Advanced/Metastatic HER2-positive Breast, Gastric, Gastroesophageal Junction Cancer With Disease Progression Following Anti-HER2 Standard of Care Treatment | 12/23 | 12/23 | | |
